1. Home
  2. TIC vs MLYS Comparison

TIC vs MLYS Comparison

Compare TIC & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Acuren Corporation

TIC

Acuren Corporation

N/A

Current Price

$11.24

Market Cap

1.9B

Sector

N/A

ML Signal

N/A

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

N/A

Current Price

$16.38

Market Cap

1.9B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TIC
MLYS
Founded
1991
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
1.9B
IPO Year
2025
2023

Fundamental Metrics

Financial Performance
Metric
TIC
MLYS
Price
$11.24
$16.38
Analyst Decision
Buy
Strong Buy
Analyst Count
6
11
Target Price
$12.64
★ $43.56
AVG Volume (30 Days)
1.8M
★ 1.9M
Earning Date
11-05-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 37.43
EPS
★ N/A
N/A
Revenue
★ $1,530,296,000.00
N/A
Revenue This Year
$47.20
N/A
Revenue Next Year
$6.28
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.36
$14.91
52 Week High
$11.86
$47.00

Technical Indicators

Market Signals
Indicator
TIC
MLYS
Relative Strength Index (RSI) 65.13 34.04
Support Level $8.87 N/A
Resistance Level N/A $31.19
Average True Range (ATR) 0.56 1.44
MACD 0.12 -0.17
Stochastic Oscillator 84.46 15.26

Price Performance

Historical Comparison
TIC
MLYS

About TIC Acuren Corporation

TIC Solutions Inc is a provider of tech-enabled Testing, Inspection, Certification and Compliance (TICC), engineering, and geospatial services. It provides mission-critical services that are essential to the safety, reliability, and efficiency of industrial assets, buildings and public infrastructure. The company's services are often non-discretionary and are driven by regulatory requirements, customer risk management policies, and the need to extend the useful life of critical assets. It operates in North America and serve both public- and private-sector clients. Its public-sector clients include federal, state, and municipal agencies, public utilities, and environmental regulators. Its private-sector clients span industrial, infrastructure, construction, and real estate end markets.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

Share on Social Networks: